Influence of irradiated lung volumes on perioperative morbidity and mortality in @entity1 after neoadjuvant radiochemotherapy for XXXX .

@entity1 @entity1143 @entity55 @entity5 @entity649 @entity900 @entity260 @entity358 @entity418 @entity1487 @entity647
PURPOSE: In some randomized trials, the treatment outcome of locally advanced @entity418 has been significantly improved by neoadjuvant radiochemotherapy (RCT). However, increased perioperative @entity358 in terms of @entity649 ( @entity649 ) has been linked to radiation exposure of the lungs. In our study we evaluated perioperative morbidity and mortality in @entity1 with @entity5 Stages IIA-IVA treated with curative intent either with surgery alone (S) or with neoadjuvant RCT followed by surgery (RCTS). @entity1 AND METHODS: Between 1996 and 2003, 55 @entity1 received S, and 98 received RCTS. In the RCTS group, most @entity1 received two cycles of @entity1487 plus @entity900 simultaneously with normofractionated radiotherapy (40Gy). Four weeks later they underwent surgery. Endpoints were the incidence of @entity647 ( @entity647 ), @entity649 , other @entity260 , and mortality within 31 days. RESULTS: Between both groups there were no significant differences between the incidence and severity of @entity647 and @entity649 (RCTS: 42.9%, 42.9%; S: 45.5%, 38.2%). Furthermore, there were no significant differences in the incidences of @entity55 , @entity1143 , and pneumothorax (RCTS 29.6% vs. S 16.4%, p = 0.07). Perioperative complication rates and mortality did not vary significantly (mortality after RCTS 5.1% vs. S 3.6%). A detailed analysis of 54 RCTS @entity1 according to lung dose-volume histograms did not show any correlation between @entity649 and pulmonary exposure. In univariate analysis, only respiratory comorbidity correlated with @entity649 . CONCLUSION: Neoadjuvant @entity900 and @entity1487 -based RCT apparently has no detrimental impact on the postoperative course.
